# Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT

> **NCT01379391** · PHASE4 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation
- Myeloablative
- Delayed Platelet Engraftment

## Interventions

- **DRUG:** Recombinant Human Thrombopoietin (rHTPO)

## Key facts

- **NCT ID:** NCT01379391
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06
- **Primary completion:** 2015-09
- **Final completion:** —
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2015-10-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379391, "Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01379391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*